"ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific" was originally created and published by ...

Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

Bristol Myers Squibb is ending its collaboration with Immatics on IMA401, effective December 12, as part of portfolio ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

Immatics has been left with the full rights to develop a bispecific molecule after its partner Bristol Myers Squibb (BMS) cut ties with the project. BMS has handed back both the development and ...

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on ...

An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company.

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up. In its third-quarter results update ...